Copyright
©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Diabetes. Mar 15, 2015; 6(2): 245-258
Published online Mar 15, 2015. doi: 10.4239/wjd.v6.i2.245
Published online Mar 15, 2015. doi: 10.4239/wjd.v6.i2.245
Diabetic cardiac autonomic neuropathy: Do we have any treatment perspectives?
Victoria A Serhiyenko, Alexandr A Serhiyenko, Department of Endocrinology, National Medical University named after Danylo Galytski, 79017 Lviv, Ukraine
Author contributions: Serhiyenko VA performed the literature search and wrote first draft; Serhiyenko AA provided expert opinion and reviewed the paper.
Conflict-of-interest: The authors have no conflict of interest.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Dr. Victoria A Serhiyenko, Department of Endocrinology, National Medical University named after Danylo Galytski, 69 Pekarska Str., 79017 Lviv, Ukraine. serhiyenko@inbox.ru
Telephone: +380-322-769496
Received: August 28, 2014
Peer-review started: August 30, 2014
First decision: September 28, 2014
Revised: October 24, 2014
Accepted: December 29, 2014
Article in press: December 30, 2014
Published online: March 15, 2015
Peer-review started: August 30, 2014
First decision: September 28, 2014
Revised: October 24, 2014
Accepted: December 29, 2014
Article in press: December 30, 2014
Published online: March 15, 2015
Core Tip
Core tip: Cardiac autonomic neuropathy (CAN) is a serious complication of diabetes mellitus, that is strongly associated with increased risk of cardiovascular mortality. CAN manifests in a spectrum of things, ranging from resting tachycardia and fixed heard rate to development of “silent” myocardial infarction. Although it is common complication, the significance of CAN has not been fully appreciated and there are no unified treatment algorithms for today. In this review we have analyzed the effectiveness of lifestyle modification, prescription of α-lipoic acid, aldose reductase inhibitors; γ-linoleic acid, acetyl-L-carnitine, antioxidants, long-chain ω-3 polyunsaturated fatty acids, vasodilators, vitamin B1 and some other substances.